These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Teyton L, O'Sullivan D, Dickson PW, Lotteau V, Sette A, Fink P, Peterson PA. Nature; 1990 Nov 01; 348(6296):39-44. PubMed ID: 2234057 [Abstract] [Full Text] [Related]
25. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Ghosh P, Amaya M, Mellins E, Wiley DC. Nature; 1995 Nov 30; 378(6556):457-62. PubMed ID: 7477400 [Abstract] [Full Text] [Related]
27. Conformation of MHC class II I-A(g7) is sensitive to the P9 anchor amino acid in bound peptide. Gardiner A, Richards KA, Sant AJ, Arneson LS. Int Immunol; 2007 Sep 30; 19(9):1103-13. PubMed ID: 17855434 [Abstract] [Full Text] [Related]
28. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Germain RN, Rinker AG. Nature; 1993 Jun 24; 363(6431):725-8. PubMed ID: 8515815 [Abstract] [Full Text] [Related]
30. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain. Fineschi B, Sakaguchi K, Appella E, Miller J. J Immunol; 1996 Oct 15; 157(8):3211-5. PubMed ID: 8871612 [Abstract] [Full Text] [Related]
31. Cell surface expression of class II MHC proteins bound by a single peptide. Ignatowicz L, Winslow G, Bill J, Kappler J, Marrack P. J Immunol; 1995 Apr 15; 154(8):3852-62. PubMed ID: 7706725 [Abstract] [Full Text] [Related]
32. The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM. Peterson M, Sant AJ. J Immunol; 1998 Sep 15; 161(6):2961-7. PubMed ID: 9743359 [Abstract] [Full Text] [Related]
33. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens. Cheng PC, Steele CR, Gu L, Song W, Pierce SK. J Immunol; 1999 Jun 15; 162(12):7171-80. PubMed ID: 10358163 [Abstract] [Full Text] [Related]
34. Assembly of major histocompatibility complex class II subunits with invariant chain. Neumann J, Koch N. FEBS Lett; 2005 Nov 07; 579(27):6055-9. PubMed ID: 16242130 [Abstract] [Full Text] [Related]
35. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism. Doebele RC, Pashine A, Liu W, Zaller DM, Belmares M, Busch R, Mellins ED. J Immunol; 2003 May 01; 170(9):4683-92. PubMed ID: 12707347 [Abstract] [Full Text] [Related]
36. DM-mediated release of a naturally occurring invariant chain degradation intermediate from MHC class II molecules. Stebbins CC, Peterson ME, Suh WM, Sant AJ. J Immunol; 1996 Dec 01; 157(11):4892-8. PubMed ID: 8943393 [Abstract] [Full Text] [Related]
37. Structural principles of MHC class II antigen presentation. Nelson CA, Fremont DH. Rev Immunogenet; 1999 Dec 01; 1(1):47-59. PubMed ID: 11256572 [Abstract] [Full Text] [Related]
38. DR/CLIP (class II-associated invariant chain peptides) and DR/peptide complexes colocalize in prelysosomes in human B lymphoblastoid cells. Stang E, Guerra CB, Amaya M, Paterson Y, Bakke O, Mellins ED. J Immunol; 1998 May 15; 160(10):4696-707. PubMed ID: 9590215 [Abstract] [Full Text] [Related]
39. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes. Siebenkotten IM, Carstens C, Koch N. J Immunol; 1998 Apr 01; 160(7):3355-62. PubMed ID: 9531295 [Abstract] [Full Text] [Related]
40. [Analysis of the allele specific Ag-binding site on murine class II MHC]. Kajino K. Hokkaido Igaku Zasshi; 1996 Mar 01; 71(2):187-203. PubMed ID: 8641675 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]